EA202091493A1 - AMORPHOUS LETERMOVIR AND SOLID PHARMACEUTICAL PREPARATIONS CONTAINING IT, INTENDED FOR ORAL ADMINISTRATION - Google Patents

AMORPHOUS LETERMOVIR AND SOLID PHARMACEUTICAL PREPARATIONS CONTAINING IT, INTENDED FOR ORAL ADMINISTRATION

Info

Publication number
EA202091493A1
EA202091493A1 EA202091493A EA202091493A EA202091493A1 EA 202091493 A1 EA202091493 A1 EA 202091493A1 EA 202091493 A EA202091493 A EA 202091493A EA 202091493 A EA202091493 A EA 202091493A EA 202091493 A1 EA202091493 A1 EA 202091493A1
Authority
EA
Eurasian Patent Office
Prior art keywords
amorphous letermovir
intended
letermovir
solid pharmaceutical
pharmaceutical preparations
Prior art date
Application number
EA202091493A
Other languages
Russian (ru)
Inventor
Вильфрид Шваб
Дирк Юнг
Кристиан Шикканедер
Велльянне Мертенс
Михаэль Лиммерт
Клеменс Боте
Матиас Берве
Николе Риндерманн
Original Assignee
Аикурис Анти-Инфектив Курес Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аикурис Анти-Инфектив Курес Гмбх filed Critical Аикурис Анти-Инфектив Курес Гмбх
Publication of EA202091493A1 publication Critical patent/EA202091493A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к аморфному летермовиру и содержащим его перорально вводимым твердым фармацевтическим препаратам (препараты немедленного высвобождения). Указанный аморфный летермовир является подходящим для приготовления препаратов немедленного высвобождения, если его выделяют из органического раствора путем сушки в вальцовой сушилке указанного органического раствора в летучем органическом растворителе, предпочтительно в ацетоне, при температуре от 30 до 60°C, с последующей сушкой полученного аморфного летермовира, или если указанный аморфный летермовир выделяют путем осаждения из смешивающихся с водой растворителей, выбранных из ацетона или ацетонитрила, путем добавления к избытку воды, использующейся в качестве антирастворителя, с последующим фильтрованием или центрифугированием полученного аморфного летермовира. Содержащие аморфный летермовир препараты немедленного высвобождения предназначены для применения в способах профилактики или в способах лечения заболеваний, связанных с вирусами семейства Herpesviridae, предпочтительно связанных с цитомегаловирусом (CMV), еще более предпочтительно связанных с цитомегаловирусом человека (HCMV).The present invention relates to amorphous letermovir and orally administered solid pharmaceutical preparations (immediate release preparations) containing it. Said amorphous letermovir is suitable for the preparation of immediate release preparations if it is isolated from an organic solution by roller drying said organic solution in a volatile organic solvent, preferably acetone, at a temperature of 30 to 60 ° C, followed by drying the resulting amorphous letermovir, or if said amorphous letermovir is isolated by precipitation from water-miscible solvents selected from acetone or acetonitrile, by adding to an excess of water as an anti-solvent, followed by filtration or centrifugation of the resulting amorphous letermovir. The immediate release formulations containing amorphous letermovir are intended for use in methods of preventing or in methods of treating diseases associated with viruses of the Herpesviridae family, preferably associated with cytomegalovirus (CMV), even more preferably associated with human cytomegalovirus (HCMV).

EA202091493A 2014-04-16 2014-06-19 AMORPHOUS LETERMOVIR AND SOLID PHARMACEUTICAL PREPARATIONS CONTAINING IT, INTENDED FOR ORAL ADMINISTRATION EA202091493A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14165027 2014-04-16

Publications (1)

Publication Number Publication Date
EA202091493A1 true EA202091493A1 (en) 2020-09-11

Family

ID=50624411

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091493A EA202091493A1 (en) 2014-04-16 2014-06-19 AMORPHOUS LETERMOVIR AND SOLID PHARMACEUTICAL PREPARATIONS CONTAINING IT, INTENDED FOR ORAL ADMINISTRATION

Country Status (1)

Country Link
EA (1) EA202091493A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115463102A (en) * 2022-09-26 2022-12-13 湖北科益药业股份有限公司 Acyclovir tablet and preparation method thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115463102A (en) * 2022-09-26 2022-12-13 湖北科益药业股份有限公司 Acyclovir tablet and preparation method thereof
CN115463102B (en) * 2022-09-26 2023-11-24 湖北科益药业股份有限公司 Acyclovir tablet and preparation method thereof

Similar Documents

Publication Publication Date Title
EA201600024A1 (en) AMORPHOUS LETERMOVIR AND CONTAINING IT SOLID PHARMACEUTICAL PREPARATIONS INTENDED FOR ORAL ADMINISTRATION
EA201891494A1 (en) HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
MX2020010484A (en) Substituted heterocyclyl derivatives as cdk inhibitors.
UY36674A (en) DERIVATIVES OF INDOL MONO OR DISABLED AS INHIBITORS OF THE REPLICATION OF DENGUE VIRUSES
MA39783B1 (en) Quinoxaline derivatives useful as modulators of fgfr kinase
EA201892216A1 (en) SUBSTITUTED INDIN DERIVATIVES AS AN INHIBITORS OF DENG VIRUS REPLICATION
ECSP18073264A (en) DERIVATIVES FROM INDOLE COMPOUNDS SUBSTITUTED AS INHIBITORS OF THE VIRAL REPLICATION OF DENGUE
EA201892219A1 (en) SUBSTITUTED INDIN DERIVATIVES AS AN INHIBITORS OF DENG VIRUS REPLICATION
EA201491548A1 (en) 2'-SUBSTITUTED CARBANECULOSE ANALOGUES FOR ANTI-VIRUS TREATMENT
EA201892214A1 (en) SUBSTITUTED DERIVATIVES OF INDOL AS AN INHIBITORS OF DENG VIRUS REPLICATION
BR112017002190A2 (en) dihydropteridinone derivatives and uses thereof
UY36518A (en) DERIVATIVES OF INDOL MONO OR DISABLED AS INHIBITORS OF THE REPLICATION OF DENGUE VIRUSES
BR112017002369A2 (en) diazepan derivatives and uses thereof
EA201790949A1 (en) SUBSTITUTED 2,4-DIAMINOCHINOLINES AS NEW ANTI-CANCER FACILITIES
EA202190588A1 (en) HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
EA202191478A1 (en) HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
PH12016502039A1 (en) Potent and selective inhibitors of hepatitis c virus
EA201692111A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DANIRYXIN FOR TREATING INFECTIOUS DISEASES
EA202091493A1 (en) AMORPHOUS LETERMOVIR AND SOLID PHARMACEUTICAL PREPARATIONS CONTAINING IT, INTENDED FOR ORAL ADMINISTRATION
EA202191477A1 (en) HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
EA201792170A1 (en) INDOLA DERIVATIVES
MA39533A1 (en) Compounds, pharmaceutical composition and their use in the treatment of neurodegenerative diseases
EA202090666A1 (en) APPLICATION OF BENZOATE-CONTAINING COMPOSITION FOR TREATMENT OF GLYCINE ENCEPHALOPATHY
TH165370A (en) Amorphous Thermovir and its pharmaceutical solids formulations for oral administration.
TH165370B (en) Amorphous Thermovir and its pharmaceutical solids formulations for oral administration.